Видео ютуба по тегу T-Cell Redirection

T Cell Redirection Therapy | Tarek Mouhieddine, MD | ASH 2022
T Cell Redirection Therapy | Tarek Mouhieddine, MD | ASH 2022
Bispecific Antibodies for T‐Cell Redirection Therapy
Bispecific Antibodies for T‐Cell Redirection Therapy
What Are T-Cell Redirecting Therapies? A Simple Guide for Multiple Myeloma Patients
What Are T-Cell Redirecting Therapies? A Simple Guide for Multiple Myeloma Patients
Relapse Options: How T-Cell Redirecting Therapies Target Myeloma
Relapse Options: How T-Cell Redirecting Therapies Target Myeloma
Redirection of T cells against HBV-infected cells
Redirection of T cells against HBV-infected cells
The use of CELMoDs to improve outcomes with T-cell redirection therapies in RRMM
The use of CELMoDs to improve outcomes with T-cell redirection therapies in RRMM
Redirecting T-cell cytotoxicity and proliferation
Redirecting T-cell cytotoxicity and proliferation
The Mark-and-Kill Approach of CD-19 Redirected ARTEMIS T Cell
The Mark-and-Kill Approach of CD-19 Redirected ARTEMIS T Cell
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Driving Robust ADCC and T Cell Redirection with KILR CD16 Effector Cells
Driving Robust ADCC and T Cell Redirection with KILR CD16 Effector Cells
Mechanisms of resistance to T-cell redirecting therapies
Mechanisms of resistance to T-cell redirecting therapies
CD19-Redirected ARTEMIS T Cells
CD19-Redirected ARTEMIS T Cells
T-cell redirecting therapies for R/R multiple myeloma
T-cell redirecting therapies for R/R multiple myeloma
Dr. Martha Louzada - T-cell Redirecting Therapy & Highlights of ASH
Dr. Martha Louzada - T-cell Redirecting Therapy & Highlights of ASH
T-Cell Redirection: The Future of Myeloma Treatment Explained!
T-Cell Redirection: The Future of Myeloma Treatment Explained!
Transplant versus T-cell redirecting therapies in the upfront setting for multiple myeloma
Transplant versus T-cell redirecting therapies in the upfront setting for multiple myeloma
Highlights at ASH 2022: the promise of T-cell redirecting therapies in multiple myeloma
Highlights at ASH 2022: the promise of T-cell redirecting therapies in multiple myeloma
Redirected T Cells Target Cardiac Fibrosis
Redirected T Cells Target Cardiac Fibrosis